Lundbeck Presents New Data at AAN 2026 Highlighting Real-World Changes in Migraine-Related Cognitive Symptoms After Starting VYEPTI® (eptinezumab-jjmr)
The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide (anti-CGRP) treatment failure DEERFIELD, Ill.–(BUSINESS WIRE)–Lundbeck today presented new real-world 6-month results from the INFUSE study at the American Academy of Neurology (AAN) 2026 Annual Meeting, underscoring the importance … [Read more…]
